Search our team at AdventHealth Research Institute
Showing 97 - 108 of 154 clinical trials available
-
NCT05633654
GS-US-595-6184 A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63; NCT05633654)
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer Research -
Deep-learning of digital histopathology, radiomics and clinical factors to develop precision medicine with first-line gemcitabine-cisplatin-nivolumab for metastatic urothelial carcinoma: analysis of the CHECKMATE901 Phase III trial
This study is not currently enrolling.Associated Conditions: Urothelial CancerResearch Area: Clinical Cancer Research -
NCT04585750
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is not currently enrolling.Research Area: Clinical Cancer Research -
E303-1001S: A Phase I/II, Open-label, Multi-center, First-in-human Trial to Investigate E303 in Participants with Unresectable or Metastatic Solid Tumors and Urothelial Carcinoma
This study is not currently enrolling.Research Area: Clinical Cancer Research -
NCT05083481
A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
This study is not currently enrolling.Research Area: Clinical Cancer Research -
A Phase 1b/2a, Multicenter, Open-Label Study of Pocenbrodib as Monotherapy and in combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
This study is not currently enrolling.Associated Conditions: Prostate CancerResearch Area: Clinical Cancer Research -
NCT05155332
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors.
This study is not currently enrolling.Research Area: Clinical Cancer Research -
NCT06819007
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer” GOG 3112/ DSI-T-DXd ENHERTU (DO-01); DESTINY-Ovarian01 (DO-01)] DS8201-772
This study is not currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study consists of two parts: Part 1 (safety run-in) and Part 2 (randomized part [like the flip of a coin]). The purpose of Part 1 is to learn more about the safety and tolerability of the...
-
NCT05929235
A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
This study is not currently enrolling.Associated Conditions: Urothelial CancerResearch Area: Clinical Cancer ResearchResearch Location: Celebration, Florida -
NCT05514717
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2
This study is not currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe purpose of the study is to: During the Dose Escalation part, find the most tolerated dose of the Study Drug that may provide potential benefit. During the Enrichment and Expansion parts, further...
-
NCT06172478
A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is not currently enrolling.Research Area: Clinical Cancer ResearchThe purpose of this study is to learn more about an investigational drug called patritumab deruxtecan (also known as HER3-DXd or U3-1402), also referred to as “study drug” or “study treatment”...
-
NCT06456463
A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer Research